MktsMarkets

Monte Rosa Therapeutics, Inc.
NASDAQ: GLUEKey statistics
GLUE News
Stories mentioning GLUE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 44,069 | 41,979 | 36,678 | 30,653 | 32,190 | 38,866 | 27,616 | 28,055 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 54,244 | 52,496 | 45,743 | 38,748 | 40,893 | 47,643 | 35,743 | 37,337 |
| Operating Income (Loss) | (50,034) | (49,715) | (32,975) | (15,554) | 44,036 | 13,004 | (26,527) | (32,642) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (44,451) | (46,076) | (30,258) | (11,096) | 47,707 | 15,601 | (23,788) | (30,058) |
| Tax Provision | 52.00 | 59.00 | (3,177) | 1,199 | 822.00 | 2,164 | 71.00 | 252.00 |
| Net Income (Loss) | (44,503) | (46,135) | (27,081) | (12,295) | 46,885 | 13,437 | (23,859) | (30,310) |
| Earnings Per Share (Basic) | (0.56) | 0.18 | ||||||
| Earnings Per Share (Diluted) | (0.56) | 0.18 | ||||||
| Weighted Average Shares Outstanding (Basic) | 99,884 | 83,071 | 82,398 | 82,187 | 82,149 | 73,910 | 82,012 | 71,234 |
| Weighted Average Shares Outstanding (Diluted) | 99,884 | 83,071 | 82,398 | 82,187 | 82,956 | 73,910 | 82,012 | 71,234 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About GLUE
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a stock listed on the Nasdaq Stock Market under the ticker symbol GLUE. It last traded at $10.57 (Nov 6, 2026, 4:00 PM ET), up 3.1% on the day. That gives Monte Rosa Therapeutics a market capitalisation of $901.8M.
Over the past 52 weeks GLUE has traded between $9.68 and $25.77.
For the quarter ended Mar 31, 2026 it reported a net loss of $44.5M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$44.5M |
| Dec 31, 2025 | — | -$46.1M |
| Sep 30, 2025 | — | -$27.1M |
| Jun 30, 2025 | — | -$12.3M |
From Monte Rosa Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…